Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q1KCI Q2
- 저널
- GUT AND LIVER18(1) · pp.70 · 2024
- 피인용
- Web of Science 3Scopus 3KCI 2
- FWCI (Scopus)
- 0.38
- JCR IF
- JCR 2023 3.4
- ISSN
- 1976-2283
저자
- Kim, Jie-Hyun제1저자Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
- Jung, Hwoon-YongUniv Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea
- Yoo, In KyungCha Bundang Med Ctr, Dept Internal Med, Div Gastroenterol, Seongnam, South Korea
- Park, Seon-YoungChonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, South Korea
- Kim, Jae GyuChung Ang Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea
- Sung, Jae KyuChungnam Natl Univ, Dept Internal Med, Coll Med, Daejeon, South Korea
- Jang, Jin SeokDong A Univ, Dept Internal Med, Coll Med, Busan, South Korea
- Cheon, Gab JinUniv Ulsan, Gangneung Asan Hosp, Dept Internal Med, Coll Med, Kangnung, South Korea
- Kim, Kyoung OhGachon Univ, Gil Med Ctr, Dept Gastroenterol, Coll Med, Incheon, South Korea
- Kim, Tae OhInje Univ, Coll Med, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea
- Lee, Soo TeikJeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Dept Internal Med, Div Gastroenterol,Med Sch, Jeonju, South Korea
- Cho, Kwang BumKeimyung Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sch Med, Daegu, South Korea
- Chun, Hoon JaiKorea Univ, Dept Gastroenterol, Anam Hosp, Seoul, South Korea
- Park, Jong-JaeKorea Univ, Dept Gastroenterol, Guro Hosp, Seoul, South Korea
- Park, Moo InKosin Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Busan, South Korea
- Jang, Jae-YoungKyung Hee Univ, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul, South Korea
- Jeon, Seong WooKyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea
- Cho, Jin WoongPresbyterian Med Ctr, Dept Internal Med, Jeonju, South Korea
- 강대환Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea
- 김광하Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Dept Internal Med,Coll Med, Busan, South Korea
- Kim, Jae J.Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
- Kim, Sang GyunSeoul Natl Univ, Seoul Natl Univ Hosp, Liver Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea
- Kim, NayoungSeoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
- Lee, Yong ChanYonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
- Hong, Su JinSoonchunhyang Univ, Dept Internal Med, Coll Med, Bucheon, South Korea
- Kim, Hyun-SooWonju Severance Christian Hosp, Dept Internal Med, Wonju, South Korea
- Lee, SoraDaewon Pharmaceut, Clin R&D Dept, Seoul, South Korea
- Lee, Sang Woo교신저자Korea Univ, Dept Gastroenterol, Ansan Hosp, Ansan, South Korea
초록
Background/Aims: H2 receptor antagonists (H2RA) have been used to treat gastritis by inhibit-ing gastric acid. Proton pump inhibitors (PPIs) are more potent acid suppressants than H2RA. However, the efficacy and safety of low-dose PPI for treating gastritis remain unclear. The aim was to investigate the efficacy and safety of low-dose PPI for treating gastritis.Methods: A double-blind, noninferiority, multicenter, phase 3 clinical trial randomly assigned 476 patients with endoscopic erosive gastritis to a group using esomeprazole 10 mg (DW1903) daily and a group using famotidine 20 mg (DW1903R1) daily for 2 weeks. The full-analysis set in-cluded 319 patients (DW1903, n=159; DW1903R1, n=160) and the per-protocol set included 298 patients (DW1903, n=147; DW1903R1, n=151). The primary endpoint (erosion improvement rate) and secondary endpoint (erosion and edema cure rates, improvement rates of hemorrhage, erythema, and symptoms) were assessed after the treatment. Adverse events were compared.Results: According to the full-analysis set, the erosion improvement rates in the DW1903 and DW1903R1 groups were 59.8% and 58.8%, respectively. According to the per-protocol analysis, the erosion improvement rates in the DW1903 and DW1903R1 groups were 61.9% and 59.6%, respectively. Secondary endpoints were not significantly different between two groups except that the hemorrhagic improvement rate was higher in DW1903 with statistical tendency. The number of adverse events were not statistically different.Conclusions: DW1903 of a low-dose PPI was not inferior to DW1903R1 of H2RA. Thus, low-dose PPI can be a novel option for treating gastritis (ClinicalTrials.gov Identifier: NCT05163756). (Gut Liver, Published online June 13, 2023)
키워드
GastritisPhase III clinical trialProton pump inhibitorsHistamine H2 antagonistsSYMPTOM RELIEFOMEPRAZOLEDA-9601DISEASE
식별자
- Scopus EID
- 2-s2.0-85182501593
- WoS UID
- 001013085200001
- KCI
- ART003044276



로그인
연구물 목록으로